Published online Oct 15, 2023. doi: 10.4251/wjgo.v15.i10.1807
Peer-review started: May 31, 2023
First decision: July 31, 2023
Revised: August 20, 2023
Accepted: September 14, 2023
Article in press: September 14, 2023
Published online: October 15, 2023
Processing time: 131 Days and 17.8 Hours
To evaluate the clinicopathological features and prognosis of gastric cancer (GC) occurring synchronously with gastrointestinal stromal tumor (GIST).
We report 19 patients with concurrent GC and GIST (17 male and 2 female, median age 62 years). GC was most often located in the lower third of the stomach. GIST was diagnosed preoperatively in four patients. GIST was most often located in the gastric body (n = 8, 42%). The most common growth pattern in GIST was extraluminal (n = 12, 63%). The positive expression rates of CD117 and CD34 in GIST were 100% and 95%, respectively. Most patients with GIST (n = 17, 89%) were very low or low risk. There was no recurrence of GIST during follow-up. The 3-year cumulative survival rate was 73.9%, and the 5-year cumulative survival rate was 59.2%. The combined analysis of this study and literature reports (47 reports, 157 patients) found that GC and GIST were usually located in the lower third (42%) and middle third (51%) of the stomach. GC was usually early (stage I: 42%), poorly differentiated (42%) intestinal-type adenocarcinoma (51%). GISTs were primarily small in diameter (median: 1.2 cm) and very low or low risk (89%).
Synchronous GC and GIST may not be rare. They have specific clinicopathological characteristics, and may have mutual inhibition in pathogenesis and progression.
Core Tip: We conclude that there are specific clinicopathological features in gastric cancer (GC) and gastrointestinal stromal tumor (GIST), as is often seen in older men; GC is usually a poorly differentiated enterotype early adenocarcinoma located in the lower third of the stomach. GIST is usually small in diameter, low or very low risk, and located in the body of the stomach. We hypothesized that GC and GIST might be affected by the same unknown carcinogen, leading to the simultaneous proliferation of epithelial and mesenchymal cells. GC and GIST may inhibit each other in the occurrence and development of the disease.